Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gene Therapy For Lethal Glycogen Storage Disease Wins EMA PRIME Designation

Ten products have been granted PRIME designation so far this year

Executive Summary

Investigational products from Ultragenyx and MinervaX secured a place on the European Medicines Agency’s priority medicines scheme this month.

You may also be interested in...



MinervaX Hopes To Match Pfizer In Group B Streptococcus Vaccines Race

The Danish biotech has secured more funding for a late-stage program to advance its vaccine against Group B streptococcus, which is in a race for approval with Pfizer's product.

PRIME Dry Spell Over As EMA Says Yes To Pfizer & BioCryst

This year’s first designations under the European Medicines Agency’s priority medicines scheme have gone to a maternal vaccine for an infection in newborns and a treatment for an ultra-rare bone disorder.

Outlook To Make Its Case For Ophthalmic Bevacizumab At High-Stakes EMA Meeting

Outlook Therapeutics is hoping to secure EU marketing approval for the first ophthalmic formulation of bevacizumab.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel